Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner

Pharmacological Research

Volumn 61, Issue 1, 2010, Pages 58-61

  Nakamura, Tsukasa ^a   Sato, Eiichi ^a   Fujiwara, Nobuharu ^a   Kawagoe, Yasuhiro ^a   Ueda, Yoshihiko ^b   Suzuki, Tsukasa ^b   Ueda, Seiji ^c   Fukami, Kei ^c   Okuda, Seiya ^c   Yamagishi, Sho ichi ^c  

^a Shinmatsudo Central General Hospital   (Japan)

^b DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CKD; Ezetimibe; L FABP; Oxidative stress; Proteinuria

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CHOLESTEROL; EZETIMIBE; FATTY ACID BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; PITAVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; DYSLIPIDEMIA; FEMALE; HUMAN; MALE; MONOTHERAPY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RENAL PROTECTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTICHOLESTEREMIC AGENTS; ARGININE; AZETIDINES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DEOXYGUANOSINE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROTEINURIA; QUINOLINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 73049118951     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.07.011     Document Type: Article

References (30)

1. Yamagishi S., Matsui T., and Nakamura K. Atorvastatin and diabetic vascular complications. Curr Pharm Des 12 (2006) 1549-1554
2. Yamagishi S., Nakamura K., Matsui T., Sato T., and Takeuchi M. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Med Hypotheses 66 (2006) 844-846
3. Bays H.E., Neff D., Tomassini J.E., and Tershakovec A.M. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther 6 (2008) 447-470
4. Dembowski E., and Davidson M.H. Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 16 (2009) 183-188
5. Romayne Kurukulasuriya L., Athappan G., Saab G., Whaley Connell A., and Sowers J.R. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence. Ther Adv Cardiovasc Dis 1 (2007) 49-59
6. Agarwal R. Effects of statins on renal function. Mayo Clin Proc 82 (2007) 1381-1390
7. Samuelsson O., Mulec H., Knight-Gibson C., Attman P.O., Kron B., Larsson R., et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12 (1997) 1908-1915
8. Shepherd J., Kastelein J.J., Bittner V., Deedwania P., Breazna A., Dobson S., et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2 (2007) 1131-1139
9. Fried L.F. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 74 (2008) 571-576
10. Imai E., Horio M., Nitta K., Yamagata K., Iseki K., Hara S., et al. Estimation of glomerular filtration rate by MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11 (2007) 41-50
11. Matsuguma K., Ueda S., Yamagishi S., Matsumoto Y., Kaneyuki U., Shibata R., et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 17 (2006) 2176-2183
12. Saito S., Yamauchi H., Hasui Y., Kurashige J., Ochi H., and Yoshida K. Quantitative determination of urinary 8-hydroxyguanosine (8-OHdG) by using ELISA. Res Commun Mol Pathol Pharmacol 107 (2000) 39-44
13. Kamijo A., Sugaya T., Hikawa A., Yamanouchi M., Hirata Y., Ishimitsu T., et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease. A multicenter trial. J Lab Clin Med 145 (2005) 125-133
14. Burton C., and Harris K.P. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 27 (1996) 765-775
15. D'Amico G., and Bazzi C. Pathophysiology of proteinuria. Kidney Int 63 (2003) 809-825
16. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
17. Fellström B.C., Jardine A.G., Schmieder R.E., Holdaas H., Bannister K., Beutler J., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 (2009) 1395-1407
18. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res, doi:10.1016/j.phrs.2009.04.011.
19. Nakagami H., Osako M.K., Takami Y., Hanayama R., Koriyama H., Mori M., et al. Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis 203 (2009) 51-58
20. Agarwal R., Vasavada N., Sachs N.G., and Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65 (2004) 2279-2289
21. Dincer Y., Sekercioglu N., Pekpak M., Gunes K.N., and Akcay T. Assessment of DNA oxidation and antioxidant activity in hypertensive patients with chronic kidney disease. Ren Fail 30 (2008) 1006-1011
22. Nakamura T., Sugaya T., Kawagoe Y., Suzuki T., Ueda Y., Koide H., et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 333 (2007) 321-326
23. Caglar K., Yilmaz M.I., Sonmez A., Cakir E., Kaya A., Acikel C., et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 70 (2006) 781-787
24. Yilmaz M.I., Saglam M., Caglar K., Cakir E., Sonmez A., Ozgurtas T., et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47 (2006) 42-50
25. Yamagishi S., Ueda S., Nakamura K., Matsui T., and Okuda S. Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des 14 (2008) 2613-2618
26. Lin K.Y., Ito A., Asagami T., Tsao P.S., Adimoolam S., Kimoto M., et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106 (2002) 987-992
27. Sorrenti V., Mazza F., Campisi A., Vanella L., Li Volti G., and Di Giacomo C. High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylaminohydrolase expression in endothelial cells. Curr Neurovasc Res 3 (2006) 49-54
28. Ziyadeh F.N., and Goldfarb S. The renal tubulointerstitium in diabetes mellitus. Kidney Int 39 (1991) 464-475
29. Tojo A., Kimoto M., and Wilcox C.S. Renal expression of constitutive NOS and DDAH: separate effects of salt intake and angiotensin. Kidney Int 58 (2000) 2075-2083
30. Yokoyama T., Kamijo-Ikemori A., Sugaya T., Hoshino S., Yasuda T., and Kimura K. Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am J Pathol 174 (2009) 2096-2106